Pregnancy and Lactation: There is no data from the use of Gefitinib in pregnant or breast-feeding women. Studies in animals have shown reproductive toxicity. Animal studies also indicate that Gefitinib and certain metabolites pass into rats breast-milk. Women of childbearing potential must be advised to avoid becoming pregnant, and breast-feeding mothers must be recommended to discontinue nursing while receiving GEFITERO therapy.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
